Patent ID: 8048640

Claim:
A method for identifying a test agent as a candidate for treating human prostate cancer or benign prostatic hyperplasia comprising: i) providing a mouse, wherein the mouse comprises a human prostate primary xenograft, wherein the xenograft comprises blood vessels, wherein the blood vessels comprise human vascular endothelial cells and human epithelial cells; ii) initiating androgen deprivation in the mouse; iii) administering to the mouse the test agent within a period of 1-7 days after initiating the androgen deprivation; iv) determining in the mouse from iii) a reduction in human endothelial cells in the xenograft, wherein the reduction of the endothelial cells in the xenograft is determined by measuring an increase in fibrin association index from the xenograft, and wherein the reduction in the endothelial cells in the xenograft relative to a human prostate primary xenograft in a control mouse to which the agent has not been administered is indicative that the agent is a candidate for treating human prostate cancer or prostatic hyperplasia in an individual.